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Summary. Recent findings of impaired mitochondrial function, altered iron 
metabolism and increased lipid peroxidation in the substantia nigra in 
Parkinson's disease emphasize the significance of oxidative stress and free 
radical formation in the pathogenesis of the disease. Future research will focus 
on improvements in neuroprotective therapy to prevent or slow the rate of 
progression of Parkinson's disease. Possible neuroprotective strategies include 
free radical scavengers, monoamine oxidase-B inhibitors, iron chelators and 
glutamate antagonists. 
Introduction 
Parkinson's disease is characterized pathologically by loss of catechol-
aminergic neurones in the brainstem (German et al., 1989; Jellinger, 1991). 
The degeneration of the melanin-pigmented dopaminergic neurones of the 
substantia nigra pars compacta is the neuropathological basis of the movement 
disorders characterizing Parkinson's disease. When about 80% of the neurones 
are lost the motor symptoms appear (Riederer and Wuketich, 1976). The cause 
of degeneration of dopamine-containing neurones in Parkinson's disease is 
unknown. 
The search for evidence supporting a genetic aetiology for Parkinson's 
disease has long been hampered by uncertainties regarding nosology and 
neuropathology of the disease. Twin studies showing similar concordance rates 
between monozygotic and dizygotic twins with Parkinson's disease suggested 
that inheritance plays little or no part in the aetiology of the disease (Ward et 
al., 1983; Marsden, 1987; Marttila et al., 1988). A reappraisal of the twin study 
by Ward et al. (1983) concluded that a genetic component of Parkinson's 
disease cannot be ruled out (Johnson et al., 1990). Two large kindreds of 
familial Parkinson's disease have shown an autosomal dominant mode of 
transmission of clinically rather atypical, but pathologically classical 
Parkinson's disease (Golbe et al., 1990). A recent study using strict diagnostic 
criteria has shown that familial Parkinson's disease exists and is clinically 
indistinguishable from sporadic Parkinson's disease (Maraganore et al., 1991). 
The role of genetic factors in the aetiology of sporadic cases of Parkinson's 
disease remains to be determined. 
The incidence of Parkinson's disease increases with advancing age. How-
ever, the hypothesis that Parkinson's disease is the result of an interaction 
between age-related nigrostriatal dopamine loss and secondary insults has 
recently been challenged. Post-mortem measurement of striatal dopamine 
uptake terminals demonstrated decreasing striatal innervation with ageing, but 
no difference in the rate of terminal loss between young and old patients was 
found (Scherman et al., 1989). Positron emission tomography studies pro-
duced conflicting results with regard to alterations of striatal [18F]fluorodopa 
uptake with age. In cross-sectional studies of normal volunteers both a de-
crease (Martin et a l , 1989) and no change (Sawle et al., 1990) in striatal 
dopamine uptake have been found. The failure to show an age-related 
dopamine depletion in normal subjects makes an acute event as the cause of 
Parkinson's disease more likely. In a longitudinal study, a reduction in 
dopamine uptake was observed in both normal subjects and patients with 
Parkinson's disease, and the rate of change was comparable in both groups 
(Bhatt et al., 1991). This data suggests that Parkinson's disease results from 
sudden damage of unknown origin in the past rather than from a gradual 
acceleration of dopamine loss. The suggestion that ageing does not contribute 
significantly to the evolution of Parkinson's disease is supported by histologi-
cal studies showing that in normal brains the number of pigmented substantia 
nigra cells is reduced by only 4.7 to 6.0% per decade from the fifth to the ninth 
decade of life (Gibb and Lees, 1991). Parkinson's disease may be the result of 
a toxic insult during early life which reduces the number of dopaminergic 
neurones in the substantia nigra and the further decline of this number with 
ageing may finally produce the symptoms of the disease. Recent research on 
the pathogenesis of Parkinson's disease has focussed on the possible involve-
ment of neurotoxins as a cause of Parkinson's disease. 
Involvement of neurotoxins in Parkinson's disease 
The discovery that the neurotoxin l-methyl-4-phenyl-l,2,3,6-tetrahydro-
pyridine (MPTP) induces neuropathological and neurochemical alterations as 
well as clinical signs very similar to those of Parkinson's disease suggests that 
a similar chemical compound may cause Parkinson's disease (Ballard et al., 
1985; Burns et al., 1985). The chemical structure of MPTP is similar to that of 
many pyridines found in the environment and, in particular, to that of chemi-
cals commonly used in agriculture (Snyder and D'Amato, 1986). Several case-
control studies have shown associations between Parkinson's disease and rural 
living, well-water drinking and exposure to herbicides and pesticides (Tanner 
and Langston, 1990). A recent case-control study from Kansas has shown that 
rural residence and drinking well-water, but not farming and herbicide expo-
sure, were increased in patients with Parkinson's disease compared with 
control subjects (Wong et al., 1991). Another case-control study from Calgary 
compared patients with Parkinson's disease with randomly selected commu-
nity controls and did not find an increased risk for the development of 
Parkinson's disease associated with a history of rural residence, farm living or 
well-water drinking in early childhood or at any time during the first 45 years 
of life (Semchuk et al., 1991). Possible explanations for the conflicting 
findings are difficulties with regard to the diagnosis of Parkinson's disease, 
different definitions of positive exposure or length and timing of the exposure 
period. An alternative explanation is that geographic variation exists in the 
relationship between rural environmental factors and the risk of developing 
Parkinson's disease. 
Although environmental toxins may contribute to the aetiology of 
Parkinson's disease, chronic intoxication by selective exposure to a specific 
agent is unlikely because Parkinson's disease is widespread throughout the 
world. Endogenous substances with neurotoxic actions similar to those of 
MPTP may exist; possible compounds include tetrahydroisoquinolines (Saitoh 
et al., 1988) and beta-carbolines (Drucker et al., 1990). It is also possible that 
MPTP and related agents do not cause Parkinson's disease but rather provide 
clues to the mechanism underlying neuronal death in this disease. 
Oxidation reactions in Parkinson's disease 
It has been suggested that excess free radical formation plays a role in the 
pathogenesis of Parkinson's disease (Graham et al., 1978; Spina and Cohen, 
1989; Youdim et al., 1990). There are two theoretical concepts of how 
oxidation reactions and toxic oxygen species may contribute to the degenera-
tive process underlying neuronal death in Parkinson's disease. 
The first concept proposes that excess formation of free radicals occurs as a 
result of toxin action. The neurotoxin MPTP expresses its toxicity as a 
consequence of its oxidation to the l-methyl-4-phenyl-pyridinium ion (MPP +) 
by monoamine oxidase type B (MAO-B) (Chiba et al., 1984; Salach et al., 
1984; Heikkila et a l , 1985). Inhibition of the oxidation of MPTP to M P P + by 
M A O - B inhibitors such as deprenyl and pargyline prevents the neurotoxic 
effects of MPTP and the development of a parkinsonian syndrome in animal 
models of Parkinson's disease (Cohen et al., 1984; Heikkila et al., 1984; 
Langston et al., 1984b). If Parkinson's disease is caused by MPTP-like 
compounds, oxidation reactions may be essential for the development of 
Parkinson's disease. The toxic effects of M P P + are thought to be caused by its 
ability to inhibit complex I of the mitochondrial respiratory chain (Nicklas 
Table 1. Evidence supporting a state of oxidative stress in the substantia nigra in 
Parkinson's disease 
- Disturbed mitochondrial respiratory function with reduction in complex I and III 
activities 
- Altered cellular calcium homoeostasis with decrease in calcium-binding protein 
- Decreased glutathione and glutathione peroxidase activity leading to a reduced ability to 
scavenge hydrogen peroxide derived from oxidative deamination and auto-oxidation of 
dopamine 
- Increased iron content resulting in a potential excess of radical-generating free iron 
- Increased mitochondrial superoxide dismutase activity, perhaps reflecting an attempt to 
compensate for oxidative stress 
- Increased peroxidation of membrane lipids inducing membrane damage and cell death 
et al., 1985; Vyas etal., 1986) resulting in decreased cellular adenosine 
triphosphate levels (Di Monte et al., 1986) and altered intracellular calcium 
content (Kass et al., 1988). Alterations in the homoeostasis of intracellular 
calcium are closely linked with altered cell function and cell death (Orrenius et 
al., 1989). Recent studies have shown that the calcium binding protein 
calbindin is selectively decreased in the substantia nigra in Parkinson's disease 
(Iacopino and Christakos, 1990). The inhibition of mitochondrial function may 
also lead to increased formation of free radical species. 
The second concept concerning the importance of oxidation reactions and 
free radical formation in the pathogenesis of Parkinson's disease relates to the 
metabolism of dopamine. Dopamine can be oxidatively metabolized by the 
enzyme monoamine oxidase (MAO). The polymerization of auto-oxidative 
products of dopamine leads to the formation of neuromelanin and the charac-
teristic pigmentation of the substantia nigra. Both auto-oxidation of dopamine 
and oxidative deamination by M A O result in the formation of hydrogen 
peroxide (H 2 0 2 ) . Under normal circumstances H 2 0 2 is rather inert and never 
accumulates in the brain or other organs. H 2 0 2 is normally cleared from the 
brain by the glutathione system. Glutathione peroxidase catalyzes the reaction 
of H 2 0 2 with glutathione (GSH) to form glutathione disulfide (GSSG): 
Glutathione 
peroxidase 
H 2 0 2 + 2 GSH 2 H 2 0 + GSSG 
In the presence of iron, H 2 0 2 can be reduced to form the toxic hydroxyl free 
radical (Fenton reaction): 
H.Oo + Fe 2 + OH + OH- + Fe 3 + 
M A O activity in the brain increases with ageing (Fowler et al., 1980) and this 
may lead to an increase in the formation of H 2 0 2 which could exceed the 
capacity of the glutathione system. Similarly, a reduction in glutathione or 
glutathione peroxidase could prevent the clearance of H 2 0 2 generated from 
normal dopamine metabolism. The result of either of these mechanisms could 
be the insufficient clearance of H 2 0 2 and the production of hydroxyl free 
radicals which may cause damage to dopamine-containing cells. 
Recent research on the biochemical pathology of Parkinson's disease 
indicates that free radicals generated from oxidation reactions are important 
for the neuronal loss in the substantia nigra in Parkinson's disease (see 
Table 1). 
Oxidative stress as a cause of Parkinson's disease 
The recent discovery of complex I deficiency in the substantia nigra in 
Parkinson's disease (Schapira et al., 1990a) raised the possibility that the dis-
ease may be caused by a similar mechanism to MPTP-induced parkinsonism. 
Complex I deficiency in Parkinson's disease appears to be anatomically spe-
cific for the substantia nigra (Schapira et al., 1990b) and probably reflects 
some active process selectively affecting this area. 
The absence of complex I deficiency in multiple system atrophy (Schapira et 
al., 1990b) indicates that this defect is not the result of neuronal degeneration in 
the substantia nigra. An MPTP-like substance may inhibit complex I of 
mitochondrial energy metabolism. Alternatively, complex I deficiency could 
result from a defective gene encoding abnormal complex I proteins or a factor 
that regulates gene transcription. Using immunoblotting analysis, mitochondrial 
D N A has been reported to be normal in the substantia nigra, putamen and cortex 
of patients with Parkinson's disease (Lestienne et al., 1990). Studies using the 
polymerase chain reaction have shown an increase in deletion of striatal 
mitochondrial D N A in both Parkinson's disease and senescence (Ikebe et al., 
1990; Lestienne et al., 1991). The deleted genome may therefore not be a specific 
property of Parkinson's disease but rather the result of ageing. 
The inhibition of mitochondrial function may lead to increased formation 
of radical species in several ways including an overspill of superoxide radicals 
from the electron transport chain. Free radicals are capable of reacting almost 
instantaneously with membrane lipids and causing lipid peroxidation, altera-
tions in membrane fluidity and eventually cell death. In the substantia nigra of 
patients with Parkinson's disease an increase in the basal formation of 
malondialdehyde, a stable intermediate in the peroxidative process, coupled 
with a decrease in the levels of polyunsaturated fatty acids, the substrate for 
lipid peroxidation, has been shown (Dexter et a l , 1989a). 
Superoxide dismutase converts superoxide, a free radical involved in 
MPTP neurotoxicity, to hydrogen peroxide. In the substantia nigra in 
Parkinson's disease an increase in the activity of the mitochondrial form of this 
enzyme has been reported with no change in total or cytosolic enzyme activity 
(Saggu et a l , 1989). This data suggests an increased formation of superoxide 
radicals in proximity to mitochondria inducing an increase in superoxide 
dismutase activity. 
Iron-melanin interaction in Parkinson's disease 
The brain contains a substantially higher concentration of iron than of any 
other metal (Youdim, 1988). Within the brain iron shows an uneven distribu-
tion with high levels in the substantia nigra, striatum and globus pallidus 
(Spatz, 1924; Hallgren and Sourander, 1958; Hi l l and Switzer, 1984; Riederer 
et al., 1989). Although the function of a regionally high brain iron content is 
unknown the homoeostasis of brain iron is believed to be necessary for normal 
brain function (Youdim, 1989; Youdim et al., 1989). Free tissue metal such as 
Fe 2 + or C u 2 + can initiate the formation of cytotoxic oxygen free radicals 
resulting from its interaction with hydrogen peroxide and leading to promotion 
of membrane lipid peroxides. The mobilization of intracellular and 
mitochondrial calcium by iron is thought to be directly involved in cellular 
toxicity in oxidative stress (Braughler, 1988). 
It is now generally accepted that a selective increase in iron content occurs 
in the substantia nigra in Parkinson's disease (Riederer et al., 1989; Dexter et 
al., 1989b; Jellinger et al., 1990; Sofic et al., 1991). Histochemical and 
biochemical analyses have shown that this increase in iron is localized in the 
pars compacta of the substantia nigra (Jellinger et al., 1990; Sofic et al., 1991). 
Iron-induced oxidative stress and lipid peroxidation can proceed optimally 
with either Fe 2 + or Fe 3 + provided mechanisms exist to facilitate the inter-
conversion of iron between its redox states. Fe 3 + , when formed, can be 
converted to Fe 2 + in the presence of endogenous chelators such as adenosine 
diphosphate or melanin. Such an interaction makes Fe 3 + even more reactive as 
an initiator of 'OH production. An endogenous iron chelator in the substantia 
nigra with a high affinity for iron is melanin. The substantia nigra pars 
compacta contains excessive amounts of neuromelanin produced by the auto-
oxidation of dopamine and it is the melanin-containing dopaminergic neurones 
that degenerate in Parkinson's disease (Hirsch et al., 1988). Melanin is able to 
bind high amounts of metals but is under normal circumstances thought to 
participate in scavenging metal-induced free radicals as it does in the skin. 
However, melanin has high affinity binding sites for Fe 3 + and increased 
amounts of Fe 3 + have been found in neuromelanin of substantia nigra pars 
compacta neurones (Jellinger et al., 1992). Melanin-iron interaction leads to a 
potentiation of iron-induced basal lipid peroxidation in the presence of 
synaptosomal preparations of the rat brain cortex (Ben-Shachar and Youdim, 
1990). The potentiation of melanin-iron-induced lipid peroxidation has been 
attributed to the ability of melanin to reduce Fe 3 + to Fe 2 + while H 2 0 2 drives a 
Fenton-like reaction with liberation of cytotoxic hydroxyl radicals (Ben-
Shachar and Youdim, 1990). This process is thought to occur with Fe 3 + and not 
Fe 2 + (Pilas et al., 1988). The alteration in the ratio of Fe 2 + to Fe 3 + from 2:1 in 
the substantia nigra pars compacta of control subjects to 1:1 in parkinsonian 
patients (Sofic et al., 1991) is compatible with optimal conditions necessary 
for induction of a lipid peroxidation process (Braughler et al., 1986): 
Fe 3 + + melanin —• Fe 2 + + melanin* 
These findings suggest that oxidative stress induced by iron-melanin interac-
tion is a possible mechanism in the aetiology of Parkinson's disease without 
involving an endogenously or exogenously derived neurotoxin (Youdim et al., 
1989). 
Recent findings of animal experiments support the hypothesis that iron initi-
ates dopaminergic neurodegeneration in Parkinson's disease. Injection of iron 
into the substantia nigra of rats causes a selective decrease of striatal dopamine 
and impairment of dopamine-related behavioural responses (Ben-Shachar and 
Youdim, 1991). Furthermore, 6-hydroxydopamine lesions of nigrostriatal 
dopamine neurones can be prevented by administration of iron chelators (Ben-
Shachar et al., 1991). 6-Hydroxydopamine is thought to exert its neurotoxic 
activity via the formation of oxygen free radicals liberated from H 2 0 2 as a 
result of its oxidation (Heikkila and Cohen, 1972; Sachs and Jonsson, 1975; 
Graham et al., 1978). The prevention of 6-hydroxydopamine toxicity by iron 
chelators implies therefore that endogenous free iron interacts with H 2 0 2 
generated. 
Glutathione in Parkinson's disease 
The findings of altered iron metabolism, impaired mitochondrial function and 
increased lipid peroxidation support the importance of oxidative stress for 
neuronal degeneration in the substantia nigra of patients with Parkinson's 
disease. These alterations do not explain, however, why nigral neurones are not 
protected by normal detoxification mechanisms. Toxic compounds formed in 
the brain are normally inactivated by various protective mechanisms. These 
mechanisms, however, may be impaired in Parkinson's disease, e.g. reduced 
activity of catalase, peroxidase and glutathione peroxidase and diminished 
concentrations of reduced glutathione (GSH) have been found in the substantia 
nigra in Parkinson's disease (Ambani et al., 1975; Perry et al., 1982; Kish et 
al., 1985; Riederer et al., 1989). GSH in the substantia nigra and enzymes that 
utilize GSH for free radical detoxification, such as glutathione peroxidase and 
glutathione-S-transferase, probably play an important role in protecting 
dopamine-containing nigral neurones from damage by MPTP or from other 
MPTP-like neurotoxins which may cause Parkinson's disease in humans. 
Reduced levels of GSH have been found in the brainstem of mice following 
administration of MPTP (Yong et al., 1986; Riederer et al., 1987). 
In Parkinson's disease the surviving neurones of the nigrostriatal pathway 
exhibit an increased dopamine turnover (Hornykiewicz and Kish, 1986). This 
could theoretically be associated with oxidative stress as a consequence of 
increased production of hydrogen peroxide during the oxidative deamination 
of dopamine by M A O . In the mouse, a reserpine-induced increase in pre-
synaptic dopamine turnover caused a rise in the level of oxidized glutathione 
(glutathione disulfide, GSSG). The formation of GSSG could be blocked by 
the M A O - A inhibitor clorgyline (Spina and Cohen, 1989). Oxidative metabo-
lism of dopamine in the brain is associated with the production of hydrogen 
peroxide and may be reflected by oxidation of GSH to GSSG (Sies, 1983; 
White et al., 1986). A recent study has shown that the concentration of GSH is 
reduced in the substantia nigra of patients with Parkinson's disease compared 
with control subjects while the concentration of GSSG is unaltered (Sofic et 
al., 1992). The decreased concentration of nigral GSH in Parkinson's disease 
could be the result of neuronal loss, since a positive correlation has been found 
between the GSH content and the severity of neuronal depletion in the 
parkinsonian brain (Riederer et al., 1989). However, neuronal degeneration 
does not appear to be the only explanation for the GSH reduction observed, 
since GSSG was not decreased to the same extent as GSH and the percentage 
of GSSG of the total glutathione was slightly increased (Sofic et al., 1992). The 
reduction in GSH levels may provide a target for therapeutic intervention. 
Neuroprotective strategies in Parkinson's disease 
The biochemical alterations in Parkinson's disease such as increased lipid 
peroxidation, altered iron metabolism and impairment of mitochondrial func-
tion point to oxidative stress as an important factor contributing to neuronal 
loss in the substantia nigra in Parkinson's disease. Protection against such 
oxidative damage could be provided by scavengers of free radicals and anti-
oxidants such as M A O - B inhibitors, alpha-tocopherol (vitamin E), ascorbic 
acid (vitamin C), glutathione and iron chelators (see Table 2). 
Treatment with ascorbic acid in the mouse has been reported to reverse the 
decrease in striatal dopamine levels caused by the systemic administration of 
MPTP or focal injection of M P P + into the striatum (Sershen et al., 1985; 
Wagner et a l , 1985, 1986). Alpha-tocopherol has been shown to prevent nigral 
cell loss in MPTP-treated mice (Perry et al., 1985) and has been reported in an 
open-label study to retard the clinical progression of Parkinson's disease in 
therapeutically naive patients (Fahn, 1989). Another open study showed that 
parkinsonian patients taking alpha-tocopherol had less severe deficits than 
those not taking the substance (Factor et al., 1990). The ongoing DATATOP 
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Table 2. Neuroprotective strategies in Parkinson's disease 
Biochemical alterations Possible neuroprotective 
in the substantia nigra therapies 
Formation of hydrogen peroxide 
Increased iron content 
Formation of toxic oxygen 
free radicals 
Alteration in the homeostasis 
of intracellular calcium 
Excess activity of excitatory amino acids (?) 
M A O - B inhibitors (e.g. L-deprenyl) 
Iron chelators 
Free radical scavengers 
(e.g. vitamin C, vitamin E) 
Calcium entry blockers 
(e.g. nimodipine) 
Excitatory amino acid antagonists 
study (Parkinson Study Group, 1989) compares the effect of alpha-tocopherol 
and placebo on disease progression in a prospective, double-blind trial. 
The findings of a selective increase in oxidative stress and in Fe 3 + content in 
the substantia nigra in Parkinson's disease suggest that iron chelators may be 
able to prevent the retardation of the dopaminergic neurodegeneration. The 
dopaminergic neurotoxic effect of 6-hydroxydopamine is thought to involve 
the generation of oxygen free radicals (Heikkila and Cohen, 1972; Sachs and 
Jonsson, 1975; Graham et al., 1978) presumably initiated by a transitional 
metal. The administration of the iron chelator desferoxamine in the rat 
protects against the 6-hydroxydopamine-induced reduction in striatal 
dopamine content and the development of dopamine-related behavioural 
changes (Ben-Shachar et al., 1991). The ability of iron chelators to retard 
dopaminergic neurodegeneration in the substantia nigra may indicate a new 
neuroprotective approach in Parkinson's disease. Iron chelators such as amino 
steroids have shown protective activity in animal models of trauma and 
ischaemia and are able to cross the blood-brain barrier and to inhibit iron-
dependent lipid peroxidation (Braughler et al., 1987; Hall, 1988; Hall and 
Yonkers, 1988). 
Neuroprotective action of L-deprenyl 
The selective M A O - B inhibitor L-deprenyl was initially employed as an 
adjunct to L-DOPA, based on the hypothesis that inhibition of dopamine 
metabolism would increase dopamine availability. M A O - B inhibitors increase 
brain levels of dopamine and phenylethylamine (Neff et al., 1974; Riederer et 
al., 1984) and L-deprenyl potentiates the anti-parkinsonian action of L-DOPA 
(Birkmayer et al., 1975; Elizan et al., 1991). Retrospective studies showed 
that patients who received both L-DOPA and L-deprenyl lived longer than 
patients who were treated with L-DOPA alone (Birkmayer et al., 1985). Two 
randomized, prospective, double-blind studies have compared L-deprenyl with 
placebo in otherwise untreated subjects with early Parkinson's disease 
(Parkinson Study Group, 1989; Tetrad and Langston, 1989). Both studies 
demonstrated that L-deprenyl produced a prolongation of the period before 
systematic therapy was required. L-deprenyl appears to delay the onset of 
disability and to have a neuroprotective effect by slowing the rate of progres-
sion of Parkinson's disease in newly diagnosed patients. For the first time a 
drug has been found that may influence the underlying neuropathology of the 
disease. A major argument against the neuroprotective action of L-deprenyl in 
the trial of the Parkinson Study Group (1989) has been the short wash-out 
period of one month. It has been argued that the symptomatic effects of the 
drug may still have been apparent (Landau, 1990). However, an increase in the 
concentration of amines is observed only following M A O inhibition of about 
80% (Green and Youdim, 1976). The symptomatic effect of an M A O inhibitor 
is lost relatively rapidly as the enzyme recovers from total blockade. New 
protein synthesis to levels of enzyme protein that sufficiently metabolize the 
amine appears within the first two weeks following cessation of an irreversible 
M A O inhibitor. Furthermore, urinary phenylethylamine concentrations, which 
accumulate by 20 to 90-fold following L-deprenyl administration, drop to 
normal excretion levels within a few days following L-deprenyl withdrawal 
(Elsworth et al., 1978). The design of the L-deprenyl study (Parkinson Study 
Group, 1989) appears adequate for the assessment of neuroprotective proper-
ties of the drug. 
L-deprenyl may decrease the generation of hydrogen peroxide associated 
with dopamine catabolism through its action as an M A O - B inhibitor and slow 
the progression of Parkinson's disease by reducing the death of substantia 
nigra neurones induced by endogenous neurotoxic free radicals. A neuro-
protective role of L-deprenyl has been demonstrated in the mouse. L-Deprenyl 
reduced oxidative stress associated with an increased turnover of dopamine 
induced by haloperidol and limited the accumulation of GSSG in the striatum 
(Cohen and Spina, 1989). 
The neuroprotective effects of L-deprenyl may partly be mediated by the 
antagonistic occupation of the polyamine binding site of the N-methyl-D-
aspartate (NMDA) receptor by N-acetylated polyamines such as N -
acetylputrescine, N-acetylspermidine and N-acetylspermine. These substances 
are highly selective M A O - B substrates (Youdim, unpublished observation) 
and their concentrations in the brain may be increased following L-deprenyl 
treatment. L-Deprenyl may therefore exert a neuroprotective function by a 
reduction of excessive calcium influx into neurones following antagonistic 
modulation of the polyamine binding site of the N M D A receptor. 
The inhibition of MPTP-induced neurotoxicity by L-deprenyl given prior 
to the toxin is well established. It has recently been shown that L-deprenyl 
increases the survival of substantia nigra neurones in the mouse even when the 
drug is administered days following the MPTP treatment (Tatton and Green-
wood, 1991). This finding suggests a neuroprotective mechanism that is 
independent of M A O - B activity. It can rather be related to the stimulation of 
neurotrophic factors or regenerative processes. 
Neuroprotective activity may be a generalized feature of both M A O - A and 
M A O - B inhibitors. The selective reversible M A O - A inhibitor moclobemide 
(p-chloro-N-[2-morpholinoethyl]benzamide) has been reported to have neuro-
protective effects due to the inhibition of generation of hydrogen peroxide via 
M A O - A reactions (Da Prada et al., 1990). 
Anti-glutamatergic neuroprotection 
Excitatory amino acids such as L-glutamate are neurotransmitters in the 
central nervous system of mammals (Fonnum, 1984). Excessive activity of 
excitatory amino acids has been postulated to play a role in a variety of 
neurodegenerative diseases including Parkinson's disease (Olney, 1989). This 
hypothesis is based on findings showing neurotoxic properties of both L -
glutamate (Olney, 1969) and substances exciting the main glutamate receptor 
subtypes, i.e. N-methyl-D-aspartate (NMDA), quisqualate or alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate. Microinjec-
tions of many excitatory amino acids into various brain areas can produce an 
acute reaction that selectively destroys certain neurones in the area (McGeer et 
al., 1978; Rothman and Olney, 1987). 
There is evidence indicating that excitatory amino acids are involved in the 
neurotoxic effects of MPTP. Systemic administration of MPTP to humans and 
non-human primates causes parkinsonian motor deficits associated with a 
selective destruction of dopamine-containing neurones in the substantia nigra 
pars compacta and a marked reduction in striatal dopamine content (Davis et 
al., 1979; Langston et al., 1983, 1984a; Burns et al., 1983). Neurotoxicity 
appears to be due to the formation of l-methyi-4-phenylpyridinium ion 
(MPP +) (Sanchez-Ramos et al., 1988; Lange, 1990) which is the result of the 
metabolism of MPTP by monoamine oxidase type B (MAO-B) . M P P + is 
subsequently transported by the dopamine uptake process to accumulate 
within dopaminergic neurones and to be temporarily stored in a releasable pool 
(Javitch et al., 1985). The toxicity of M P P + apparently occurs as the result of 
inhibition of complex I of the mitochondrial respiratory chain (Nicklas et al., 
1985). 
It has been shown that glutamate antagonists, which block the N M D A 
subtype of receptor, protect dopaminergic nigral neurones against destruction by 
MPP+injected directly into the substantia nigra of rats (Turski etal., 1991). Since 
rats are less sensitive to M P P + than primates, the doses of the toxin needed to 
produce brain damage are very high and could cause unspecific toxic effects. In 
the mouse, the non-competitive NMDA-receptor antagonist (+)-5-methyl-
10,11 -dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine maleate (MK-801) has 
been shown to be ineffective in preventing the dopamine depletion induced by 
systemic administration of MPTP (Sonsalla et al., 1989). Recent studies in mon-
keys, however, have demonstrated that glutamate antagonists are able to modu-
late the neurotoxicity of MPTP. The competitive N M D A antagonist 3-((±)-2-
carboxypiperazin-4-yl)-propyl-1 -phosphonic acid (CPP) protects tyrosine 
hydroxylase-positive neurones in the substantia nigra from degeneration induced 
by systemic treatment with MPTP in the common marmoset (Lange et al., 1992). 
The non-competitive N M D A antagonist MK-801 prevents the development of 
the parkinsonian syndrome in the cynomolgus monkey (Zuddas et al., 1992) and 
protects nigral tyrosine hydroxylase-positive neurones in cynomolgus monkeys 
(Zuddas et al., 1992) and marmosets (Lange et al., unpublished observation) 
from degeneration following the administration of MPTP. 
The neuroprotective action of N M D A receptor antagonists against MPTP 
toxicity supports the hypothesis that N M D A receptor-mediated events are 
involved in the neurotoxicity of MPTP and MPP + . M P P + interferes with 
mitochondrial respiration and depletes cell energy resources (Nicklas et al., 
1985). Neuronal energy deprivation could alter the normal functioning of cell 
membranes and cause a partial depolarization leading to a relief of the voltage 
dependent M g 2 + block of N M D A receptor ion channels (Nowak et al., 1984). 
Removal of the M g 2 + block enables excitatory amino acids to excite their 
receptors persistently, to open the ion channels and to become neurotoxic 
(Novelli et al., 1988). 
The neurotoxic effects of excitatory amino acids may be involved in the 
pathogenesis of Parkinson's disease (Calne et al., 1986). Other forms of 
parkinsonism have been linked with toxic action of excitatory amino acids on 
dopaminergic cells in the substantia nigra. The amyotrophic lateral sclerosis-
parkinsonism-dementia complex of Guam is thought to be caused by the 
amino acid P-N-methylamino-L-alanine (Spencer et al., 1987) which has been 
shown to activate glutamate receptors (Weiss and Choi, 1988). Concussive 
brain injuries are associated with increased extracellular excitatory amino acid 
concentrations (Faden et al., 1989) and can cause nigrostriatal degeneration 
and parkinsonism in boxers with dementia pugilistica (Mawdsley and 
Ferguson, 1963). 
The findings demonstrating neuroprotective effects of competitive and 
non-competitive N M D A antagonists in MPTP-treated monkeys suggest that 
the clinical trial of N M D A antagonists in patients with Parkinson's disease 
should be performed. The 1-amino-adamantanes amantadine and memantine, 
which are in use as antiparkinsonian drugs, have been shown to be non-
competitive N M D A antagonists (Kornhuber et a l , 1991). Whether or not these 
compounds have neuroprotective properties and whether they may be able to 
delay the progression of Parkinson's disease is unknown. If neuroprotective 
effects of N M D A antagonists can be shown in humans, then a novel strategy 
for the neuroprotective or even preventive therapy of Parkinson's disease 
could be available. 
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